KYMR · Kymera Therapeutics, Inc. · Documents

Nov 3

Current report 8-K Events of Oct 31

Financial results, Director or officer change, or executive pay, Regulation FD disclosure

Nov 3

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $9.55M ▼ 53.0% Net loss $43M Diluted EPS -$0.79

Oct 13

Current report 8-K

Regulation FD disclosure

Aug 19

Current report 8-K

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Aug 9

Earnings call

Q2 2022 earnings call

Aug 9

Current report 8-K

Financial results

Aug 9

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $11.51M ▼ 37.8% Net loss $40.26M Diluted EPS -$0.78

Jul 8

Current report 8-K Events of Jul 1

Director or officer change, or executive pay

Jun 16

Current report 8-K Events of Jun 15

Shareholder vote results

May 3

Earnings call

Q1 2022 earnings call

May 3

Current report 8-K

Financial results

May 3

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $9.62M ▼ 48.6% Net loss $36.68M

Apr 29

Proxy statement DEF 14A Meeting Jun 15, 2022

Proxy statement

Apr 29

Proxy statement DEFA14A

Proxy statement

Apr 11

Current report 8-K Events of Apr 6

Director or officer change, or executive pay

Feb 24

Current report 8-K

Financial results

Feb 24

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $72.83M ▲ 114.0% Net loss $100.22M

Jan 18

Current report 8-K Events of Jan 17

Director or officer change, or executive pay

Dec 27

Current report 8-K Events of Dec 20

Entered into a material agreement, New debt or off-balance-sheet obligation

Dec 16

Current report 8-K

Other events

Nov 10

Current report 8-K

Financial results

Nov 10

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $20.34M ▲ 39.9% Net loss $28.58M

Oct 27

Current report 8-K

Regulation FD disclosure, Other events

Oct 1

Registration statement S-3ASR

Registration statement

Sep 16

Current report 8-K

Director or officer change, or executive pay

Aug 6

Current report 8-K

Financial results

Aug 6

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $18.52M ▲ 463.2% Net loss $24.66M

Jun 28

Current report 8-K

Regulation FD disclosure, Other events

Jun 28

Registration statement S-1

Registration statement

Jun 17

Current report 8-K Events of Jun 16

Shareholder vote results

May 6

Current report 8-K

Financial results

May 6

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $18.7M ▲ 445.6% Net loss $13.08M

Apr 30

Proxy statement DEF 14A Meeting Jun 16, 2021

Proxy statement

Apr 30

Proxy statement DEFA14A

Proxy statement

Mar 16

Current report 8-K Events of Mar 12

Director or officer change, or executive pay

Mar 11

Current report 8-K

Financial results

Mar 11

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $34.03M ▲ 1060.0% Net loss $45.59M

Mar 2

Current report 8-K

Regulation FD disclosure, Other events

Jan 12

Current report 8-K

Financial results

Nov 5

Current report 8-K

Financial results

Nov 5

Quarterly report 10-Q FY2020 Q3, ended Sep 30

Quarterly report for FY2020 Q3

Revenue $14.53M ▲ 1429.8% Net loss $7.99M

Sep 9

Current report 8-K Events of Sep 4

Director or officer change, or executive pay

Sep 1

Current report 8-K Events of Aug 27

Entered into a material agreement

Aug 25

Current report 8-K Events of Aug 20

Charter or bylaw amendment, or fiscal year change

Aug 17

Registration statement S-1/A

Registration statement

Aug 13

Registration statement S-1/A

Registration statement

Aug 5

Registration statement S-1/A

Registration statement

Jul 31

Registration statement S-1

Registration statement